During the last session, TG Therapeutics Inc. (NASDAQ:TGTX)’s traded shares were 2.11 million, with the beta value of the company hitting 2.31. At the end of the trading day, the stock’s price was $6.06, reflecting an intraday gain of 5.21% or $0.3. The 52-week high for the TGTX share is $35.94, that puts it down -493.07 from that peak though still a striking 42.57% gain since the share price plummeted to a 52-week low of $3.48. The company’s market capitalization is $971.72M, and the average intraday trading volume over the past 10 days was 2.16 million shares, and the average trade volume was 3.17 million shares over the past three months.
TG Therapeutics Inc. (TGTX) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.00. TGTX has a Sell rating from 1 analyst(s) out of 9 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.51.
TG Therapeutics Inc. (NASDAQ:TGTX) trade information
TG Therapeutics Inc. (TGTX) registered a 5.21% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 5.21% in intraday trading to $6.06 this Wednesday, 08/03/22, hitting a weekly high. The stock’s 5-day price performance is -8.87%, and it has moved by 15.43% in 30 days. Based on these gigs, the overall price performance for the year is -76.21%. The short interest in TG Therapeutics Inc. (NASDAQ:TGTX) is 20.86 million shares and it means that shorts have 6.47 day(s) to cover.
The consensus price target of analysts on Wall Street is $17.22, which implies an increase of 64.81% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $40.00 respectively. As a result, TGTX is trading at a discount of -560.07% off the target high and 33.99% off the low.
TG Therapeutics Inc. (TGTX) estimates and forecasts
Statistics show that TG Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. TG Therapeutics Inc. (TGTX) shares have gone down -48.51% during the last six months, with a year-to-date growth rate more than the industry average at 20.15% against 5.70. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 13.60% this quarter and then jump 27.70% in the quarter after that. In the rating firms’ projections, revenue will increase 183.70% compared to the previous financial year.
Revenue for the current quarter is expected to be $200k as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $1.69 million by the end of Sep 2022.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -10.50%. While earnings are projected to return -8.70% in 2022.
TG Therapeutics Inc. is due to release its next quarterly earnings between February 28 and March 04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
TG Therapeutics Inc. (NASDAQ:TGTX)’s Major holders
TG Therapeutics Inc. insiders own 8.31% of total outstanding shares while institutional holders control 71.98%, with the float percentage being 78.50%. FMR, LLC is the largest shareholder of the company, while 260 institutions own stock in it. As of Mar 30, 2022, the company held over 20.33 million shares (or 14.07% of all shares), a total value of $193.33 million in shares.
The next largest institutional holding, with 12.13 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 8.40% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $115.37 million.
Also, the Mutual Funds coming in first place with the largest holdings of TG Therapeutics Inc. (TGTX) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Jun 29, 2022 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 11.43 million shares. This amounts to just over 7.92 percent of the company’s overall shares, with a $48.59 million market value. The same data shows that the other fund manager holds slightly less at 3.72 million, or about 2.58% of the stock, which is worth about $35.39 million.